Q-Pharm Pty Ltd (Nucleus Network Pty Ltd) Trials

Q-Pharm Pty Ltd (Nucleus Network Pty Ltd)	Welcome, Profile Billing Logout

Q-Pharm Pty Ltd (Nucleus Network Pty Ltd)

Welcome, Profile Billing Logout

12 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lickliter, Jason

NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed

1/2

RoW

LASN01, Placebo

Lassen Therapeutics 1 PTY LTD

Pulmonary Fibrosis, Thyroid Eye Disease

11/24

NCT02937753: Phase 1 Single Ascending Dose Study of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers

Not yet recruiting

RoW

ANX005, IVIg, Placebo

Annexon, Inc.

Healthy Volunteers

06/17

NCT04676711: A Study of GFH312 in Healthy Subjects

Completed

RoW

GFH312, Placebo

GenFleet Therapeutics (Australia) Pty Ltd.

Toxicity, Healthy

05/22

10/22

NCT04994912: First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Recruiting

RoW

EI-001, Placebo

Elixiron Immunotherapeutics Limited

Healthy

02/25

04/25

NCT05275465: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Completed

RoW

HH-006, Placebo

Huahui Health

Hepatitis B

12/22

NCT05391880: Study of Orally Administered BEBT-503 in Healthy Subjects

Completed

RoW

BEBT-503 20mg, BEBT-503 40mg, BEBT-503 80mg, BEBT-503 120mg, BEBT-503 180mg, placebo 20mg, placebo 40mg, placebo 80mg, placebo 120mg, placebo 180mg

BeBetter Med Inc

Healthy Subjects

05/23

07/23

NCT04925050: First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk

Recruiting

RoW

VB0004, Matching Placebo for VB0004

Syneos Health

Hypertension

12/23

01/24

Griffin, Paul

REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated

409

Europe, US, RoW

Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo

Dompé Farmaceutici S.p.A

Infectious Pneumonia, Severe COVID-19

09/24

NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting

9320

RoW

CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD

Novavax

COVID-19

02/25

02/26

NCT05734040: Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

Completed

478

RoW

OVX836 480µg, Fluarix Tetra, Afluria Quad, Placebo

Osivax, Novotech (Australia) Pty Limited, Mater Misericordiae Limited

Influenza

08/23

01/24

NCT04495933: A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Completed

216

RoW

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg, Placebo

The University of Queensland, Syneos Health, Coalition for Epidemic Preparedness Innovations

SARS-CoV2, Covid19

04/24

NCT05116865: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

Completed

RoW

HH-120 Dose 1, HH-120, HH-120 Dose 2, HH-120 Dose 3, Placebo

Huahui Health

COVID-19 Respiratory Infection

05/22

08/22

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Lickliter, Jason

NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed

1/2

RoW

LASN01, Placebo

Lassen Therapeutics 1 PTY LTD

Pulmonary Fibrosis, Thyroid Eye Disease

11/24

NCT02937753: Phase 1 Single Ascending Dose Study of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers

Not yet recruiting

RoW

ANX005, IVIg, Placebo

Annexon, Inc.

Healthy Volunteers

06/17

NCT04676711: A Study of GFH312 in Healthy Subjects

Completed

RoW

GFH312, Placebo

GenFleet Therapeutics (Australia) Pty Ltd.

Toxicity, Healthy

05/22

10/22

NCT04994912: First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Recruiting

RoW

EI-001, Placebo

Elixiron Immunotherapeutics Limited

Healthy

02/25

04/25

NCT05275465: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Completed

RoW

HH-006, Placebo

Huahui Health

Hepatitis B

12/22

NCT05391880: Study of Orally Administered BEBT-503 in Healthy Subjects

Completed

RoW

BEBT-503 20mg, BEBT-503 40mg, BEBT-503 80mg, BEBT-503 120mg, BEBT-503 180mg, placebo 20mg, placebo 40mg, placebo 80mg, placebo 120mg, placebo 180mg

BeBetter Med Inc

Healthy Subjects

05/23

07/23

NCT04925050: First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk

Recruiting

RoW

VB0004, Matching Placebo for VB0004

Syneos Health

Hypertension

12/23

01/24

Griffin, Paul

REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated

409

Europe, US, RoW

Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo

Dompé Farmaceutici S.p.A

Infectious Pneumonia, Severe COVID-19

09/24

NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting

9320

RoW

Novavax

COVID-19

02/25

02/26

NCT05734040: Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

Completed

478

RoW

OVX836 480µg, Fluarix Tetra, Afluria Quad, Placebo

Osivax, Novotech (Australia) Pty Limited, Mater Misericordiae Limited

Influenza

08/23

01/24

NCT04495933: A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Completed

216

RoW

MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg, Placebo

The University of Queensland, Syneos Health, Coalition for Epidemic Preparedness Innovations

SARS-CoV2, Covid19

04/24

NCT05116865: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

Completed

RoW

HH-120 Dose 1, HH-120, HH-120 Dose 2, HH-120 Dose 3, Placebo

Huahui Health

COVID-19 Respiratory Infection

05/22

08/22

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites